Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults

A phase I clinical trial

Rosalind Rowland,1 Ansar A. Pathan,1 Iman Satti,1 Ian D. Poulton,1 Magali M.L. Matsumiya,1 Megan Whittaker,1 Angela M. Minassian,1 Geraldine A. O’Hara,1 Matthew Hamill,1,4 Janet T. Scott,1,4 Stephanie A. Harris,1 Hazel C. Poyntz,1 Cynthia Bateman,1 Joel Meyer,1 Nicola Williams,7 Sarah C. Gilbert,1 Alison M. Lawrie,1 Adrian V.S. Hill1 and Helen McShane1,*

1The Jenner Institute; University of Oxford; Oxford, UK; 2centre for Statistics in Medicine; Wolfson College Annex; University of Oxford; Oxford, UK

Current Affiliation: 3Centre for Infection; Immunity and Disease Mechanisms; Biosciences, School of Health Sciences and Social Care; Brunel University; Uxbridge, Middlesex, UK; 4MRC Human Nutrition Research; Elsie Widdowson Laboratory; Cambridge, UK. 5The Wolfson Centre for Personalised Medicine; Institute of Translational Medicine; University of Liverpool; Liverpool, UK

Keywords: phase I clinical trial, tuberculosis vaccines, heterologous prime-boost regimes, poxvirus-vectored subunit vaccines

Abbreviations: AE, adverse event; AUC, area under the curve; BCG, Mycobacterium bovis Bacille Calmette Guérin; ELISA, Enzyme Linked Immunosorbent assay; ELISpot, Enzyme Linked Immunospot; FP85A, candidate TB vaccine: FP9 expressing antigen 85A; FP9, attenuated fowlpox virus; IFNγ, interferon gamma; IL-8, interleukin 8; LTBI, latent M.tb infection; M.tb, Mycobacterium tuberculosis; MVA, Modified Vaccinia Virus Ankara; MVA85A, candidate TB vaccine: MVA expressing antigen 85A; pfu, plaque forming units; SAE, serious adverse event; SFC, spot forming cells; TB, Tuberculosis; TNFα, tumor necrosis factor alpha

The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, FP85A was evaluated alone and in heterologous prime-boost regimes with another candidate TB vaccine, MVA85A. This was an open label, non-controlled, non-randomized phase I clinical trial. Healthy previously BCG-vaccinated adult subjects were enrolled sequentially into three groups and vaccinated with FP85A alone, or both FP85A and MVA85A, with a four week interval between vaccinations. Passive and active data on adverse events were collected. Immunogenicity was evaluated by Enzyme Linked Immunospot (ELISpot), flow cytometry and Enzyme Linked Immunosorbent assay (ELISA). Most adverse events were mild and there were no vaccine-related serious adverse events. FP85A vaccination did not enhance antigen 85A-specific cellular immunity. When MVA85A vaccination was preceded by FP85A vaccination, cellular immune responses were lower compared with when MVA85A vaccination was the first immunisation. MVA85A vaccination, but not FP85A vaccination, induced anti-MVA IgG antibodies. Both MVA85A and FP85A vaccinations induced anti-FP9 IgG antibodies. In conclusion, FP85A vaccination was well tolerated but did not induce antigen-specific cellular immune responses. We hypothesize that FP85A induced anti-FP9 IgG antibodies with cross-reactivity for MVA85A, which may have mediated inhibition of the immune response to subsequent MVA85A. ClinicalTrials.gov identification number: NCT00653770.

Introduction

There were 8.8 million new cases and almost 1.5 million deaths from tuberculosis (TB) in 2010.1 While global TB incidence, death rates and prevalence are falling, new strategies are required if the Stop TB partnership targets are to be achieved.1 Developing a new vaccine is one key strategy. The existing TB vaccine, Mycobacterium bovis Bacille Calmette Guérin (BCG) is cost-effective in preventing severe disease in childhood, but prevention of adult pulmonary disease is inconsistent.2,3 Additionally, BCG is contraindicated in people infected with HIV due to the risk of disseminated BCG disease.4 Our approach is to develop a new vaccine regime to boost BCG, retaining BCG’s effectiveness in infants, while improving protection against adult pulmonary disease.

Antigen-specific T cell responses are a central requirement of vaccine-induced protection against TB. CD4+ T cells are...
Recombinant viral vectors, such as poxviruses, are a particularly effective way of boosting pre-existing T cell responses, when used in heterologous prime-boost strategies. Clinical trials of candidate malaria vaccines suggest improved boosting of antigen specific CD8+ T cells following vaccination with two heterologous recombinant poxvirus vectors.5 We have developed two non-replicating recombinant poxvirus vectored candidate vaccines, Modified Vaccinia virus Ankara (MVA) and Fowlpox virus (FP9), each encoding mycobacterial antigen 85A (85A) and named MVA85A and FP85A respectively. MVA85A has been evaluated in several clinical trials since 2002 and induces a high frequency of CD4+ T cells and modest CD8+ T cell responses in healthy and HIV and M.tb -infected human subjects in the UK and Africa.6-16 FP85A has not previously been evaluated in human subjects. Vaccinating guinea pigs sequentially with BCG, MVA85A and FP85A enhanced protection against M.tb-challenge compared with vaccination with BCG alone.17

Here, we present the results of the first clinical trial evaluating the safety and immunogenicity of FP85A vaccination of BCG-vaccinated healthy human subjects in heterologous prime-boost regimes with MVA85A. Primary outcomes were passively and actively collected adverse event (AE) data of vaccine safety. Secondary outcomes were the cellular immunogenicity (magnitude of antigen-specific T cell responses) of vaccinations, evaluated by ex-vivo interferon gamma (IFNγ) Enzyme Linked Immunospot (ELISpot) assay. In addition, cryopreserved samples were stored for further exploratory immunology assays, including analysis of soluble cytokines within the first week after vaccination.

Results

Participant flow and recruitment. Between July 2007 and January 2009, 44 subjects were screened and 31 healthy adults enrolled (Fig. 1). All participants completed follow up by January 2010. Recruitment ended before the planned sample size of 36 subjects had been enrolled, as it was not possible to extend the expiry date for FP85A.

Baseline data. There were 12 subjects each in Group 1 and Group 2 and seven subjects in Group 3 (Table 1). More females

---

**Figure 1.** CONSORT flow diagram, shows the flow of subjects through the trial. Subjects were not randomized, but allocated sequentially into Group 1, then Group 2, then Group 3, in order of enrolment. All enrolled subjects completed follow up.
than males were enrolled. Group 1 had a lower proportion of male subjects than Groups 2 and 3. The ages of subjects and pre-vaccination mycobacterial exposure were comparable between groups (Table 1).

Safety evaluation. Group 1. Following vaccination with FP85A, all subjects developed a local reaction comprising erythema and induration, followed by scaling (dry, peeling skin) (Table 2). Most subjects also reported mild vaccine-site tenderness and pruritus. Moderate feverish symptoms, associated with a body temperature of 37.7°C, were recorded on the day of FP85A vaccination by one subject. All other systemic AEs after FP85A vaccination in Group 1 were mild.

One serious AE (SAE) occurred in a subject in Group 1 (FP85A) during the time course of the trial, but was not related to vaccination. This SAE consisted of a day case hospital admission 11 months after vaccination for arthroscopy, following a knee injury sustained six months after vaccination.

Group 2. All subjects developed a local reaction (erythema and induration) following vaccination with MVA85A, consistent with previous trials.11,15,16 Most subjects also experienced mild vaccine-site tenderness and pruritus. Moderate feverish symptoms, associated with a body temperature of 37.7°C, were recorded on the day of FP85A vaccination by one subject. All other systemic AEs after FP85A vaccination in Group 2 were mild.

The proportions of subjects experiencing local reactions after FP85A in Group 2 and the diameters of local reactions were similar to those in Group 1 (Table 2). Symptoms of feverishness (in the absence of a documented fever) were reported by two subjects on the day of vaccination with FP85A (four weeks after MVA85A). All other systemic AEs after FP85A vaccination in Group 2 were mild. There were no SAEs.

Group 3. Local reactions after FP85A vaccination were as described above for Groups 1 and 2 (Table 2). All systemic AEs after FP85A vaccination in Group 3 were mild.

The peak (day 2) diameters of erythema and induration after MVA85A vaccination were larger in Group 3, when MVA85A was the second poxvirus vaccination, compared with Group 2, when MVA85A was the first poxvirus vaccination (Table 2). There was one episode of moderate sleep disturbance four days after MVA85A vaccination. All other systemic AEs after MVA85A vaccination in Group 3 were mild and there were no SAEs.

Vaccine immunogenicity determined by ex-vivo IFNγ ELISpot. The kinetics and magnitude of the antigen-specific T cell responses to stimulation with 85A peptides following FP85A and MVA85A vaccination were assessed by ex-vivo IFNγ ELISpot assay.

After FP85A vaccination in Group 1, 85A responses did not increase compared with baseline levels at screening (Fig. 2A, Table 3A).

In Group 2, MVA85A vaccination expanded 85A-specific IFNγ-secreting T cells, which peaked at week one and were still maintained above baseline at week 52 (Fig. 2A and Table 3A). The magnitude of responses was comparable to those reported in previously published trials of MVA85A in BCG-vaccinated healthy adults (data not shown).1,15,16 After subsequent FP85A vaccination at week four, responses were not boosted, but continued to fall from the peak at week one.

In Group 3, 85A responses peaked at week five, one week after MVA85A vaccination. Responses declined to pre-vaccination levels after week eight (Fig. 2A). The magnitude of responses to MVA85A in Group 3, when MVA85A was preceded by FP85A, was significantly lower compared with responses in Group 2 (Table 3B).

Evaluation of soluble Th1 cytokines in the first week after vaccination. In Group 1, serum IFNγ, tumor necrosis factor α (TNFα) and interleukin 8 (IL-8) were not detected either before or within seven days of FP85A vaccination (Fig. 2B). In Group 2, IL-8 was detected in all subjects’ serum samples seven days after MVA85A vaccination and remained detectable in three subjects’ serum samples at week four (day 28). One week after FP85A vaccination, IL-8 was only detectable in one subjects’ serum. In Group 3, none of the cytokines were detectable one week after FP85A vaccination. IL-8 was detectable on the day of MVA85A vaccination and all three cytokines were detected in one subject’s serum sample one week after MVA85A vaccination.

Anti-vector studies. Responses to CD4+ and CD8+ T cell epitopes in Vaccinia and MVA. Responses to Vaccinia CD4+ and CD8+ T
Table 2. Adverse events

| Group | 1       | 2       | 3       | 4       | 5       |
|-------|---------|---------|---------|---------|---------|
|       | Vaccine | Fp85a   | MVa85a  | Fp85a   | FP85A   |
| N     | 12      | 12      | 12      | 7       | 7       |

**Solicited local AEs:**

| Local erythema, diameter: | 12 (100%) | 12 (100%) | 12 (100%) | 7 (100%) | 7 (100%) |
|---------------------------|-----------|-----------|-----------|----------|----------|
| 31 mm (13–39) Day 0 (0–1)| 30 mm (1–48) Day 0 (0–1)| 35 mm (0–66) Day 0 (0–0)| 23 mm (7–39) Day 0 (0–0)| 55 mm (40–100) Day 0 (0–1)|

| Local induration, diameter: | 12 (100%) | 12 (100%) | 12 (100%) | 7 (100%) | 7 (100%) |
|-----------------------------|-----------|-----------|-----------|----------|----------|
| 9.5 mm (3–14) Day 0 (0–1)  | 10 mm (1–14) Day 0 (0–1)| 10 mm (0–40) Day 0 (0–0)| 9 mm (5–15) Day 0 (0–6)| 55 mm (12–100) Day 0 (0–0)|

| Local pruritus | 12 (100%) | 12 (100%) | 10 (83%) | 6 (86%) | 6 (86%) |
|---------------|-----------|-----------|----------|---------|---------|
| Day 5 (1–7)   | Day 2 (0–5)| Day 1 (0–6)| Day 3 (2–9)| Day 1 (0–4)|

| Local scaling | 12 (100%) | 12 (100%) | 10 (83%) | 7 (100%) | 5 (71%) |
|---------------|-----------|-----------|----------|---------|--------|
| Day 4 (2–7)   | Day 4 (1–4)| Day 4 (0–6)| Day 4 (1–7)| Day 4 (1–6)|

| Local tenderness | 10 (83%) | 11 (92%) | 10 (83%) | 5 (71%) | 7 (100%) |
|------------------|---------|---------|---------|--------|---------|
| Day 1 (0–6)      | Day 1 (0–5)| Day 0 (0–2)| Day 1 (0–7)| Day 0 (0–2)|

| Local warmth | 7 (58%) | 9 (75%) | 10 (83%) | 4 (57%) | 7 (100%) |
|--------------|--------|--------|---------|--------|---------|
| Day 1 (0–6)  | Day 0 (0–6)| Day 0 (0–1)| Day 1 (0–6)| Day 1 (0–1)|

**Unsolicited local AEs:**

| Scar, diameter | 3 mm (25%), 2–4 | 4 mm (33%), 2–5 | 4 mm (33%), 3–4 | 1 mm (14%), 5 | 0 mm (0%) |

**Solicited systemic AEs:**

| Arthralgia | 2 (17%) | 2 (17%) | 3 (25%) | 1 (14%) | 0 (0%) |
|------------|--------|--------|---------|--------|-------|
| Day 0      | Day 0 &1| Day 0 (0–1)| Day 3 | Day 5 | Day 18 & 4 |

| Fatigue | 6 (50%) | 7 (58%) | 6 (50%) | 3 (43%) | 4 (57%) |
|---------|--------|--------|---------|--------|--------|
| Day 2 (0–6) | Day 0 (0–4)| Day 0 (0–2)| Day 0 (0–3)| Day 1 (0–3)|

| Documented fever | 1 (8%), Day 0 | 0 (0%) | 0 (0%) | 1 (8%)* | 0 (0%) |
|------------------|--------------|-------|-------|-------|-------|

| Felt feverish   | 1 (8%) | 4 (33%) | 4 (33%) | 1 (14%) | 2 (29%) |
|-----------------|--------|--------|---------|--------|--------|
| Day 0           | Day 0 (0–2)| Day 0 (0–0)| Day 5 | Days 18 & 4 | Days 1 |

| Headache | 5 (42%) | 7 (58%) | 4 (33%) | 3 (43%) | 4 (57%) |
|----------|--------|--------|---------|--------|--------|
| Day 2 (0–6) | Day 3 (0–6)| Day 0 (0–2)| Day 1 (1–2)| Day 3 (1–4)|

| Laboratory | 0 (0%) | 0 (0%) | 1 (8%) | 0 (0%) | 2 (29%) |
|------------|-------|-------|-------|-------|-------|
| Day 1      | Day 0 | Day 0 (0–2)| Day 0 | Day 18 & 3 | Day 1 |

| Lymphadenopathy | 1 (8%) | 1 (8%) | 2 (29%) | 2 (29%) | 2 (29%) |
|-----------------|-------|-------|---------|--------|--------|
| Day 1           | Day 0| Day 0 (0–2)| Days 18 & 3 | Day 1 | Day 1 |

| Malaise | 4 (33%) | 5 (42%) | 5 (42%) | 0 (0%) | 3 (43%) |
|---------|--------|--------|---------|-------|--------|
| Day 2 (0–6) | Day 1 (0–3)| Day 0 (0–2)| Day 1 (0–3)| Day 1 |

| Myalgia | 1 (8%) | 7 (58%) | 3 (25%) | 3 (43%) | 2 (29%) |
|---------|-------|--------|---------|--------|--------|
| Day 0 | Day 0 (0–2)| Day 0 (0–1)| Day 1 (1–3)| Day 1 | Day 1 |

| Nausea | 2 (17%) | 0 (0%) | 2 (17%) | 1 (14%) | 1 (14%) |
|--------|-------|-------|-------|-------|-------|
| Days 0 & 3 | Days 0 & 2| Days 0 & 2| Days 0 & 2 | Days 0 & 2 |

**Unsolicited systemic AEs:**

| Coryzal symptoms | 1 (8%), Day 2 | 2 (17%), Day 0 | 0 (0%) | 1 (14%), Day 1 | 1 (14%), Day 4 |
|------------------|--------------|---------------|-------|----------------|----------------|

| Sleep disturbance | 0 (0%) | 0 (0%) | 0 (0%) | 2 (14%) | 2 (29%) |
|-------------------|-------|-------|-------|--------|--------|
| Days 0 & 2 | Days 0 & 2 | Days 0 & 2 | Days 0 & 2 | Days 0 & 2 |

The numbers of subjects within each group reporting each adverse event and the days of onset of each adverse event are shown. Where three or more subjects in a group reported a particular adverse event, the median day of onset is shown, with range in parentheses. The median diameter of erythema and induration measured by investigators at day two (time of peak local reaction size) is shown, with range in parentheses. *One diameter of erythema after MVa85a in Group 3 classified severe (source: subject diary card); †One diameter of induration after Fp85a in Group 1 classified severe (source: subject diary card); ‡Four diameters of induration after MVa85a in Group 3 classified severe (source: investigator measurement); §No subjects reported scarring. All reports of scars were noted by investigators. Scars were pink or hypopigmented and non-palpable; ‡Potassium 2.9 mmol/l, Bilirubin 30 mmol/l one week post-vaccination; ALT 65 and 56 IU/L respectively one week post-vaccination.
cell epitopes were detectable in some, but not all subjects, both before and after immunisation in all three groups (Fig. 3A and Table 4A). The magnitude of all anti-vector responses in all groups were considerably lower than antigen 85A responses using cryopreserved peripheral blood mononuclear cells (PBMC, (data not shown).

In Group 1, responses to the CD4+ and CD8+ epitopes increased transiently one week after FP85A vaccination (Fig. 3A).

In Group 2, responses to both epitopes increased after MVA85A vaccination and were significantly higher than baseline at week four, the time of subsequent FP85A vaccination (Fig. 3A). FP85A vaccination did not boost responses to the CD4+ or CD8+ epitopes.

In Group 3, following the transiently increased responses after FP85A vaccination at week one, responses were similar to screening levels before MVA85A vaccination at week four, and were not boosted by MVA85A vaccination (Fig. 3A).

There were no correlations between ELISpot responses to the CD4+ or CD8+ epitopes before MVA85A vaccination and 85A-specific ELISpot responses one week after MVA85A vaccination (Fig. 3A).

Insert and Vector-specific IgG levels pre and post-vaccination. IgG responses to r85A. A small, transient increase in IgG responses to recombinant 85A (r85A) was observed after FP85A vaccination in Groups 1 and 3 but not after MVA85A vaccination in Group 2 (Fig. 4A). Following the subsequent vaccinations in Group 2 (FP85A) and Group 3 (MVA85A), anti-r85ALgG levels did not increase significantly.

IgG responses to FP9. Anti-FP9 IgG levels increased after vaccination with FP85A in Group 1 (Fig. 4A and Table 4B). In Group 2, anti-FP9 IgG levels increased after MVA85A vaccination and were boosted by FP85A vaccination at week four (Fig. 4A and Table 4B). Anti-FP9 IgG levels after FP85A vaccination in Group 3 were not boosted by subsequent MVA85A vaccination (Fig. 4A and Table 4B). There was a trend toward a negative correlation between pre-MVA85A anti-FP9 IgG levels and post-MVA85A IFNγ ELISpot responses to single pool 85A in Groups 2 and 3 (Fig. 4B).

IgG Responses to MVA. Anti-MVA IgG levels peaked four weeks after MVA85A vaccination in Group 2 and were not boosted by subsequent FP85A vaccination, but remained above baseline throughout follow-up (Fig. 4 and Table 4B). Anti-MVA IgG levels did not increase significantly after FP85A vaccination but did increase after subsequent MVA85A vaccination in Group 3, peaking at week 12 and remaining above baseline until week 24 (Fig. 4). At the time of MVA85A vaccination, anti-MVA IgG levels were similar between Groups 2 and 3. There was a trend toward a negative correlation between pre-vaccination anti-MVA IgG levels and post-MVA85A vaccination IFNγ ELISpot responses to single pool 85A (Fig. 4B).

Discussion

This clinical trial provides further evidence for the safety of recombinant FP9 and MVA vectored vaccines in a healthy adult population. FP85A and MVA85A vaccines were well tolerated in all regimes. The frequencies of local and systemic AEs were comparable to previous clinical trials evaluating MVA85A vaccination and FP9 and MVA-vectored candidate malaria vaccines.11,15,16,18,19 Peak local reactions were larger in diameter in the FP85A-MVA85A regime in Group 3, compared with when MVA85A was the first vaccination. However, as previously discussed, this was not associated with increased frequency or severity of other local or systemic AEs; local reaction sizes were comparable by one week and the group size was small, so the

| Table 2. Adverse events |
|------------------------|
| Dizziness | 1 (8%), Day 0 0 (0%) 0 (0%) 0 (0%) 0 (0%) |
| Axillary pain | 1 (8%), Day 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) |
| Indigestion/ reflux | 1 (14%), Day 1 1 (8%), Day 0 0 (0%) 0 (0%) 0 (0%) |
| Rigor | 0 (0%) 0 (0%) 1 (8%), Day 0 0 (0%) 0 (0%) |

The numbers of subjects within each group reporting each adverse event and the days of onset of each adverse event are shown. Where three or more subjects in a group reported a particular adverse event, the median day of onset is shown, with range in parentheses. The median diameter of erythema and induration measured by investigators at day two (time of peak local reaction size) is shown, with range in parentheses. *One diameter of erythema after MVA85A in Group 3 classified severe (source: subject diary card); †One diameter of induration after FP85A in Group 1 classified severe (source: subject diary card); ‡Four diameters of induration after MVA85A in Group 3 classified severe (source: investigator measurement); §No subjects reported scarring. All reports of scars were noted by investigators. Scars were pink or hypopigmented and non-palpable; ¶Potassium 2.9 mmol/l, Bilirubin 30 mmol/l one week post-vaccination; ‖ALT 65 and 56 IU/L respectively one week post-vaccination.
MVA85A, but not FP85A vaccination induced strong 85A-specific cellular immunity. FP85A vaccination did not boost the responses to prior MVA85A vaccination (Group 2) and responses to MVA85A vaccination were inhibited by prior FP85A vaccination. All other local and systemic AEs in these subjects were mild and AEs were otherwise comparable between groups, as observed in previous clinical trials of FP9 and MVA vectored candidate malaria vaccines.

Figure 2. For figure legend, see page 54.
The antigen insert was therefore both present within the recombinant vector and recognizable by the adaptive immune system. The FP85A vaccine also passed annual murine potency assays, involving evaluation for antigen-specific cellular immune responses, which were lower for FP85A than MVA85A (data not shown).

To investigate the inhibitory effect of prior vaccination with FP85A on the antigen-specific response to MVA85A vaccination, CD4+ and CD8+ T cell responses were detected upon stimulation of PBMC with Vaccinia epitopes following MVA85A vaccination in Group 2, but not in Group 3. No cell-mediated responses to Vaccinia epitopes were detected following FP85A vaccination. We therefore examined the serum IgG responses to MVA and FP9. Anti-MVA IgG antibodies were detected following MVA85A vaccination, whereas no antibodies were detected following FP85A vaccination (Group 3). The same trend was observed in analysis of soluble cytokines, with IL-8 detected after MVA85A vaccination in Group 2 but not in Group 3.

Recombinant FP9-vectored vaccines induce weaker immune responses than recombinant MVA vaccines and MVA85A elicits unusually high responses compared with other recombinant MVA vaccines. In malaria vaccine clinical trials with a number of different antigen inserts, an increased IFN-γ response compared with baseline was seen in FP9-MVA regimes with a similar interval between vaccinations with different viral vectors. Given the strong immune responses to MVA85A vaccination, we would expect at least modest antigen-specific immune responses following vaccination with FP85A.

Identity polymerase chain reaction (PCR) and sequencing assays had confirmed the presence of the 85A insert within the FP9 vector and no wild type FP9 was present. The clinical grade FP85A vaccine also passed annual murine potency assays, involving evaluation for antigen-specific cellular immune responses, which were lower for FP85A than MVA85A (data not shown). The antigen insert was therefore both present within the recombinant vector and recognizable by the adaptive immune system. In the clinical trial, FP85A induced local and systemic reactions typical of poxviruses, providing additional evidence that the viral vector was immunologically active. Positive and negative controls excluded technical problems with the assays and results were reproduced using frozen samples.

No cell-mediated responses to Vaccinia epitopes were detected following FP85A vaccination. We therefore examined the serum IgG responses to MVA and FP9. Anti-MVA IgG antibodies were detected following MVA85A vaccination.

**Table 3A: Comparison of responses to single 85A pool within groups using Wilcoxon signed rank test**

| Group   | Vaccine | Baseline responseb | Peak responsec | Median difference (range) | p value |
|---------|---------|-------------------|----------------|--------------------------|---------|
| 1       | FP85A (week 0) | 10 (0–83) | 5 (0–70) | 0 (0–16) | 0.30 |
| 2       | MVA85A (week 0) | 7 (0–113) | 1270 (430–1660) | 1234 (430–1660) | 0.002 |
| 3       | FP85A (week 4) | 415 (90–1623) | 357 (113–577) | -192 (-1140–130) | 0.02 |
| 4       | MVA85A (week 4) | 7 (0–43) | 17 (0–93) | 10 (0–73) | 0.07 |

**Table 3B: Comparison of 85A specific responses to MVA85A between groups using Mann Whitney U test**

| Measure                                      | Group 2 (n = 12)a | Group 3 (n = 7)a | Difference in medians (95% CI) | p value |
|----------------------------------------------|-------------------|-----------------|--------------------------------|---------|
| Peak (one week after MVA85A vaccination)     | 1270 (430–1660)   | 87 (17–353)     | 1085 (557–1573)                | < 0.001 |
| Median difference (95% CI)                  | 7816 (3100–18437) |                 |                                |         |
| Plateau (week 52)                           | 85 (17–630)       | 20 (3–57)       | 60 (14–270)                    | 0.01    |

Cellular IFN-γ secretion by PBMC in response to antigen 85A stimulation was evaluated using ELISpot assays to determine the number of spot forming cells (SFC). Post-vaccination responses were compared with baseline pre-vaccination responses using a paired analysis (Table 3A) and responses between groups were also compared (Table 3B). Median IFN-γ ELISpot responses to a single pool of 85A peptides are shown, with range in parentheses (units: SFC per million PBMC); Baseline responses were taken before vaccination (for the second vaccine in Groups 2 and 3, baseline responses shown are from week four); Peak responses are one week after vaccination.

![Figure 3](See opposite page). IFN-γ ELISpot responses to Vaccinia CD4+ and CD8+ T cell epitopes. (A) Longitudinal IFN-γ ELISpot responses to known Vaccinia CD4 and CD8 epitopes. Each dot represents an individual subjects’ response and median responses are connected by lines. Group 1 = FP85A vaccination week 0; Group 2 = MVA85A vaccination week 0; Group 3 = FP85A vaccination week four; Group 4 = FP85A vaccination week 0, MVA85A vaccination week four. Minimal, transient increases in Vaccinia CD8+ responses compared with baseline were observed after FP85A vaccination in Group 1. Transient responses to Vaccinia CD4+ and CD8+ epitopes were observed after MVA85A, but not FP85A vaccination in Group 2. In Group 3, responses to Vaccinia epitopes did not significantly increase after either FP85A or MVA85A vaccinations. (B) Correlation between IFN-γ ELISpot responses to Vaccinia CD4+ and CD8+ at the time of MVA85A vaccination and IFN-γ ELISpot responses to antigen 85A one week after MVA85A vaccination. Each dot represents an individual subjects’ responses. Pre-vaccination responses were from the day of MVA85A vaccination (Group 2 = week 0; Group 3 = week four). Post-vaccination responses were from samples taken one week after MVA85A vaccination (Group 2 = week one; Group 3 = week five). Circles = responses to Vaccinia CD4+ epitopes; diamonds = responses to Vaccinia CD8+ epitopes. No relationship between pre-vaccination anti-vector responses (y axes) and post-vaccination T cell responses (x axes) for MVA85A vaccination was found.
Figure 3. For figure legend, see page 56.
but not after FP85A vaccination. Anti-FP9 IgG levels increased after MVA85A vaccination as well as after FP85A vaccination, suggesting anti-FP9 IgG is cross-reactive for MVA85A.

In conclusion, FP85A vaccination was safe and well tolerated in healthy adults. However, unlike MVA85A vaccination, FP85A vaccination did not increase 85A-specific immune responses. FP85A vaccination inhibited the antigen-specific and vector-specific cellular responses to subsequent MVA85A vaccination. We speculate that anti-FP9 IgG antibodies which are cross-reactive with MVA85A may be one factor mediating the inhibition of antigen-specific cellular immune responses to vaccination with MVA85A.

Materials and Methods

Study design. This was an open label, non-randomized, Phase I safety and immunogenicity clinical trial in healthy, previously BCG-vaccinated, adult subjects.

| Table 4A: Comparison of cellular anti-vector responses within groups using Wilcoxon signed rank test |
| --- |
| Vaccinia epitopes | Group | Vaccine | Pre-vaccination | Post-vaccination | Median difference (range) | p value |
| --- | --- | --- | --- | --- | --- | --- |
| CD4* | 1 | FP85A (week 0) | 0 (0–20) | 8 (0–25) | 4 (10–20) | 0.06 |
| 2 | MVA85A (week 0) | 8 (0–28) | 13 (0–100) | 3 (10–90) | 0.12 |
| 3 | FP85A (week 4) | 19 (0–48) | 14 (2–43) | -6 (38–20) | 0.50 |
| CD8* | 1 | FP85A (week 0) | 0 (0–7) | 3 (0–13) | 3 (7–13) | 0.04 |
| 2 | MVA85A (week 0) | 3 (0–12) | 10 (0–67) | 5 (0–64) | 0.003 |
| 3 | FP85A (week 0) | 2 (0–18) | 3 (0–18) | 1 (0–5) | 0.05 |
| MVA85A (week 4) | 2 (0–18) | 3 (0–8) | 0 (-3–6) | 0.73 |

Cellular IFNγ secretion by PBMC in response to stimulation with Vaccinia CD4* and CD8* epitopes was evaluated using ELISPOT assays to determine the number of spot forming cells (SFC) (Table 4A). Serum IgG responses to FP9 and MVA were evaluated by ELISA (Table 4B). Post-vaccination responses were compared with baseline pre-vaccination responses using a paired analysis. (Table 4A) *Median IFNγ ELISPOT responses to Vaccinia CD4* and CD8* epitopes are shown, with range in parentheses (units: SFC per million PBMC); †Median IFNγ ELISPOT responses shown are from week four for the second vaccine in Group 2 and 3; ‡Post-vaccination responses shown are one week after each vaccine. (Table 4B) *Median serum IgG levels are shown, with range in parentheses (units: OD); •Post-vaccination responses shown are from week four for the second vaccine in Group 2 and 3; †Post-vaccination responses shown are four weeks after the first vaccine Groups 1, 2 and 3, and eight weeks after the second vaccine in Groups 2 and 3.

Figure 4 (See opposite page). Serum IgG ELISA responses to r85A, MVA, and FP9. (A) Longitudinal r85A IgG, FP9 IgG and MVA IgG responses detected by ELISA. Each dot represents an individual subjects’ response and median responses are connected by lines. Group 1 = FP85A vaccination week 0; Group 2 = MVA85A vaccination week 0, FP85A vaccination week four; Group 3 = FP85A vaccination week 0, MVA85A vaccination week four. Anti-vector antibody responses were generally stronger than antigen-specific anti-85A IgG responses. In Group 1, FP85A vaccination induced an FP9 IgG response, but no MVA IgG antibodies. In Group 2, MVA85A vaccination induced FP9 IgG and MVA IgG responses. Subsequent FP85A vaccination boosted the FP9 IgG response but did not boost the MVA IgG response. In Group 3, MVA85A vaccination induced an MVA IgG response, but did not boost the FP9 IgG response to prior FP85A vaccination. (B) Correlation between FP9 IgG and MVA IgG levels detectable by ELISA at the time of MVA85A vaccination and IFNγ ELISPOT responses to antigen 85A one week after MVA85A vaccination. Each dot represents an individual subjects’ responses. Pre-vaccination responses were from the day of MVA85A vaccination (Group 2 = week 0; Group 3 = week four). Post-vaccination responses were from samples taken after MVA85A vaccination (Group 2 = week 4; Group 3 = week 12). Circles = FP9 IgG levels; diamonds = MVA IgG levels. There were trends toward negative correlations between pre-MVA85A FP9 and MVA IgG levels and post-MVA85A IFNγ ELISPOT responses to single pool 85A in Groups 2 and 3.
Participants. Subjects were recruited from the Oxford region in the UK. Inclusion criteria were healthy adults; aged 18–50; BCG-vaccinated; seronegative for HIV, hepatitis B and hepatitis C viruses; no clinically significant abnormalities in hematology (full blood count), or biochemistry (sodium, potassium, creatinine, urea, albumin, bilirubin, Alkaline Phosphatase and Alanine aminotransferase) tests. Exclusion criteria were evidence of latent *M. tb* infection (LTBI) by Mantoux reaction (diameter

---

**Figure 4.** For figure legend, see page 58.
greater than 15 mm) or IFN-γ ELISpot responses to *M. tb*-specific antigens ESAT-6 or CFP-10. Mantoux tests were performed by clinically qualified investigators according to national guidelines. Females entering the study were required to have a negative pregnancy test and plans for reliable contraception for the duration of inclusion.

**Ethics.** This study was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Gene Therapy Advisory Committee (GTAC) and Site Specific Assessment performed by the Oxfordshire Research Ethics Committee (OxRecA). Written informed consent was obtained from all subjects prior to participation.

**Interventions.** Interventions were two candidate TB vaccines, FP85A and MVA85A. FP85A is a recombinant FP9 vector encoding antigen 85A. FP9 is a fully sequenced, live, highly attenuated form of a European strain of Fowlpox virus, derived by multiple passages of the wild-type Fowlpox virus in avian cells. FP85A was constructed using an established protocol. The 85A DNA sequence (derived from *M. tb* H37Rv) was ligated into the unique SmaI cloning site of the Fowlpox shuttle vector pEFL29, placing gene expression under the control of the Vaccinia virus P7.5 promoter. Recombinant viruses were prepared by in vitro recombination of the shuttle vector encoding 85A with FP9 in primary cultures of chicken embryo fibroblasts (CEFs) and selected by repeated plaque purification in CEF monolayers. The MVA85A vaccine was constructed as previously described.

Clinical grade MVA85A and FP85A vaccines were produced under Good Manufacturing Practice conditions by IDT Biologika GmbH (Dessau-Rosslau, Germany).

All vaccine doses were 5 × 10^7 plaque forming units (pfu) administered by intradermal injection into the deltoid area of the arm. The volumes of vaccine administered were 70 μl (FP85A) or 135 μl (MVA85A). In Group 1, the vaccine was administered into the opposite arm compared with BCG. In Groups 2 and 3, where two vaccines were administered with a four week interval, vaccines were injected into opposite arms.

**Sample size.** The planned sample size was 36 subjects, with 12 subjects in each group, aiming to detect frequently occurring AEs. Sample size calculations were performed using Stata 9 and 12 subjects per group gave a 90% power to detect a 40% difference in immune responses between two groups.

**Enrolment.** Subjects were allocated into three groups sequentially, in order of enrolment. Subjects in Group 1 were vaccinated with FP85A at enrolment. An interim safety analysis of FP85A vaccination was performed before enrolling subjects into Groups 2 and 3. Subjects in Group 2 were vaccinated with MVA85A at enrolment and FP85A at week four. Subjects in Group 3 were vaccinated with FP85A at enrolment and MVA85A at week four. Subjects were followed up regularly for one year following enrolment.

**Safety analysis.** Daily diary cards recording local and systemic AEs, local reaction sizes and body temperature were completed by subjects for seven days following each vaccination. Blood samples for hematology and biochemistry analyses were taken at screening and weeks one and 12 for all groups and additionally at week four for Groups 2 and 3. Solicited and unsolicited AEs were recorded by investigators in case report forms at each follow up appointment. The criteria for assigning AE severity and causality have been described previously. All AEs deemed possibly, probably or definitely related to vaccination have been reported. The transverse diameters of erythema and induration (palpable hardening of skin) were measured by clinically qualified and trained investigators two and seven days after each vaccination and four, eight, 12, 24 and 52 weeks after enrolment.

**Immunological assays.** Blood samples for exploratory immunology analyses were taken at screening and two days after vaccination and weeks one, four, eight, 12, 24 and 52 for all groups and additionally at week five for Groups 2 and 3. At each time point except day two, 50 ml lithium-heparinized blood and five ml serum sample were taken. A maximum of 20 ml blood was taken two days after vaccination. PBMC were extracted from lithium heparinized blood as previously described.

**ELISpot assays.** The principal readout for evaluating vaccine-induced cellular immunogenicity was by ex-vivo IFN-γ ELISpot assay using fresh PBMC as previously described. The antigens used were seven pools of antigen 85A peptides; a single pool of all 66 85A peptides; r85A; purified protein derivative (PPD) as described. For detection of LTBI at screening, wells were plated with ESAT-6 and CFP-10 peptides as described.

Anti-vector IFN-γ ELISpot was performed using frozen PBMCs, stored in liquid nitrogen. Cells were flash thawed at 37°C, resuspended in R10 and centrifuged at 1400 rpm for seven minutes. All samples had a viability of greater than 95%. Cells were rested overnight at 37°C, 5% CO_2 in R10 containing 10U/ml of Benzonase (Novagen) at 1 × 10^6 PBMC/ml. They were then washed and plated according to the ELISpot protocol.

Anti-vector IFN-γ responses were mapped to CD4+ (27 peptides) and CD8+ (36 peptides) T cell epitopes present in Vaccinia and MVA (Table S1). Peptides were synthesized according to the sequences obtained from published literature.

**Detection of soluble cytokines.** Serum samples from enrolled subjects were evaluated for the presence of soluble cytokines IFNγ, TNFα and IL-8. Frozen serum samples from screening and days two and seven were thawed at room temperature. To each FlowCytomix reaction, 25 μl of serum was added, and the assay performed according to the manufacturer’s instructions (FlowCytomix Basic kit and Simplex kits for IL-8, TNFα and IFNγ, Bender MedSystems). The cytokine-bound beads were detected on a Beckman Coulter CyAN flow cytometer and the results analyzed using the Bender MedSystems Flow Cytomix Pro 2.3 software.

**IgG enzyme linked immunosorbent assay (ELISA).** IgG was measured in serum samples, tested in duplicate. NUNC Immuno Plates (Fisher) were coated with r85A (5 μg/ml); FP9 (5 × 10^3 pfu/well); or MVA (5×10^5 pfu/well) in 0.05 M carbonate-bicarbonate buffer and incubated overnight at 4°C. Plates were
washed in PBS/Tween20 and blocked with 1% Casein in PBS (Fisher Scientific) for one hour, before the addition of serum, diluted 1:50 (r85A plates) or 1:100 (viral plates) in Casein. Plates containing serum were incubated for one hour and washed five times with PBS/Tween. Goat anti-human IgG alkaline phosphatase secondary antibody (Sigma) was added and plates incubated for one hour, and washed five times. Plates were developed by adding 50μl of Diethanolamine buffer (Fisher) with 4-Nitrophenol Phosphate tablet (Sigma) according to manufacturer’s recommendation and read at 13 min (r85A plates) or seven minutes (viral plates), timed from the beginning of the addition of developing buffer.

Statistical analysis. Post-vaccination responses to each stimulating antigen within each regime were compared with pre-vaccination (baseline) responses using the Wilcoxon signed-rank test (Stata Statistical Software, Release 9.0, 2005). Non-parametric tests were used as the data were not normally distributed. The overall magnitude of vaccine-induced IFNγ T cell ELISpot responses was summarized using the area under the curve (AUC) for each stimulating antigen and regime after subtracting pre-vaccination responses (Stata). AUC responses were compared between groups using the Mann Whitney U test. Where differences in AUC between groups were detected, peak comparisons were performed using the Mann Whitney U test.

Post-vaccination anti-vector cellular and humoral responses within each group were compared with pre-vaccination responses using the Wilcoxon signed-rank test. The relationship between pre-vaccination anti-vector cellular and antibody responses and vaccine-induced cellular immune responses was evaluated by calculating rank correlation coefficient (Spearman’s rho, Stata).

Disclosure of Potential Conflicts of Interest
A.A.P., S.G., A.V.S.H. and H.M.S. are named inventors on a composition of matter patent for MVA85A, and are shareholders in a Joint Venture formed for the further development of this vaccine.

Acknowledgments
We are grateful to all the trial participants. Oxford University was the sponsor for these clinical trials. HMcS is a Wellcome Trust Senior Clinical Research Fellow. AVSH is a Wellcome Trust Principal Fellow. HMcS, SCG and AVSH are Jenner Institute Investigators.

Financial Disclosure
This trial was funded by charitable grants from Europe Aid; TBVAC (EU 6th Framework Programme); The Oxford Biomedical Research Centre and the Wellcome Trust.

Supplemental Material
Supplemental material may be downloaded here: www.landesbioscience.com/journals/vaccines/article/22464

References
1. Global Tuberculosis Control. WHO report 2011. Geneva: World Health Organisation, 2011.
2. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80; PMID:16616560; http://dx.doi.org/10.1016/S0140-6736(06)68507-3.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculous. Meta-analysis of the published literature. JAMA 1994; 271:698-702; PMID:8309034; http://dx.doi.org/10.1001/jama.1994.035103500706038.
4. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rev 2007; 82:193-6; PMID:17526121.
5. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004; 84:95-101; PMID:14670350; http://dx.doi.org/10.1016/j.tube.2003.08.010.
6. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005; 174:449-55; PMID:15611270.
7. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 2011; 1:e000223; PMID:22102640; http://dx.doi.org/10.1136/bmjopen-2011-000223.
8. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Sarti I, Harris S, et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate vaccine in healthy BCG-infected adults. BMJ Open 2011; 1:e000223; PMID:22102640; http://dx.doi.org/10.1136/bmjopen-2011-000223.
9. Ora MO, Odunola AA, Owolabi OA, Brittain NJ, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011; 3:88ra36; PMID:22169753; http://dx.doi.org/10.1126/scitranslmed.3002661.
10. Scriba TJ, Tameris M, Mansoor N, Smith E, van der Merwe L, Mauff K, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011; 203:1832-43; PMID:21606542; http://dx.doi.org/10.1093/infdis/jir195.
11. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009; 179:724-33; PMID:19151191; http://dx.doi.org/10.1164/rccm.200809-1486OC.
12. Brookes RH, Hill PC, Owolai PK, Ibangi HB, Jeffries DJ, Donkor SA, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008; 3:e2921; PMID:18698342; http://dx.doi.org/10.1371/journal.pone.0002921.
13. Hawkrigg T, Scriba TJ, Golderblom S, Smith E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198:544-52; PMID:18582195; http://dx.doi.org/10.1086/590185.
14. Beveridge NE, Price DA, Cauzaa JR, Pathan AA, Sander CR, Asher TE, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, poly-functional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37:3089-100; PMID:17948267; http://dx.doi.org/10.1002/eji.200737504.
15. Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2007; 2:e1052; PMID:17997238; http://dx.doi.org/10.1371/journal.pone.0001052.
16. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huysen K, et al. Recombinant modified vaccinia virus ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; http://dx.doi.org/10.1038/nm1128.
17. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005; 73:3814-6; PMID:15908420; http://dx.doi.org/10.1128/IAI.73.6.3814-3816.2005.
18. Walther M, Woodruff J, Edele F, Jefferis D, Tongren JE, King E, et al. Innate immune responses to human malaria: heterosexual cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol 2006; 177:5736-45; PMID:17015763.
19. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, et al. Safety of recombinant fowlpox strain PFP and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026-34; PMID:16488959; http://dx.doi.org/10.1016/j.vaccine.2005.10.058.
20. Rowland R, Brittain N, Poulton ID, Minasian AM, Sander C, Porter DW, et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in Vaccinology 2012; 1:27-35; http://dx.doi.org/10.1016/j.trivac.2012.07.001.

21. Keefer MC, Frey SE, Eliaza M, Merch B, De Rosa SC, Barroso PE, et al.; NIAID HIV Vaccine Trials Network. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948-58; PMID:21216311; http://dx.doi.org/10.1016/j.vaccine.2010.12.104.

22. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biowas S, et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011; 29:7514-22; PMID:21501642; http://dx.doi.org/10.1016/j.vaccine.2011.03.083.

23. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983; http://dx.doi.org/10.1371/journal.pone.0013983.

24. Guerra S, López-Fernández LA, Conde R, Pascual-Montano A, Hashman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004; 78:5820-34; PMID:15140980; http://dx.doi.org/10.1128/JVI.78.11.5820-5834.2004.

25. Sawant KV, Cho H, Lyons M, Ly JH, McMurray DN. Guinea pig neutrophil-macrophage interactions during infection with Mycobacterium tuberculosis. Microbes Infect 2010; 12:828-37; PMID:20685596; http://dx.doi.org/10.1016/j.micinf.2010.05.009.

26. Sterling TR, Dorman SE, Chaison RE, Ding L, Hackman J, Moore K, et al. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001; 33:976-82; PMID:11528568; http://dx.doi.org/10.1086/320707.